Roche’s PiaSky Receives EU Approval as the First Monthly Subcutaneous Treatment for PNH Patients
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel monoclonal antibody designed to inhibit the complement protein C5, for the treatment…
Hinge Health and Midi Health Collaborate to Offer Comprehensive Menopause Care
Hinge Health and Midi Health have announced a partnership aimed at addressing the significant healthcare gap for women undergoing menopause. This collaboration merges Hinge Health’s expertise in movement-based support for…
MedImpact Broadens Access to Two Humira Biosimilars for New Patients
MedImpact Healthcare Systems, Inc., the largest independent provider of health solutions, technology, and pharmacy benefit services in the U.S., announced today the expansion of access to Humira biosimilars—Simlandi and adalimumab-adaz—for…
Avanzati Bioscience Secures EU Approval for Orphan Drug AKANTIOR
Avanzanite Bioscience BV, a specialty pharmaceutical company in the development stage, has announced that the European Commission (EC) has granted marketing authorization for AKANTIOR® (polihexanide), a treatment for acanthamoeba keratitis…
Correction OMNY Health Expands GLP-1 Patient Network to Over 600,000 for Enhanced Clinical Research
OMNY Health, a leader in creating compliant cross-industry data partnerships, has announced the launch of its Glucagon-Like Peptide-1 (GLP-1) data network, reinforcing its mission to democratize healthcare data. This new…
Quantum-Si Announces New Executive Team to Drive Company’s Growth in Proteomics
Quantum-Si Incorporated (Nasdaq: QSI), known as “The Protein Sequencing Company™,” has announced key leadership appointments. Effective September 17, 2024, Todd Bennett will join the company as the new Chief Commercial…
2024-2031 Analysis of Pharmaceutical Processing and Packaging Equipment Market Size, Share, Forecasts, and Trends
The new report, “Pharmaceutical Processing and Packaging Equipment Market: Size, Share, Forecast, and Trends Analysis by Formulation, Secondary Packaging, and End-of-Line Packaging – Global Forecast to 2031,” is now available…
Delcath Systems Reports Promising Study on Repeated Liver Chemosaturation
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), a leader in interventional oncology specializing in the treatment of primary and metastatic liver cancers, has announced the publication of an…
Ordspono (odronextamab) EU Approval for Treating Relapsed/Refractory Lymphomas
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that the European Commission (EC) has granted approval for Ordspono™ (odronextamab) to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)…
New Dupixent and Itepekimab Data at ERS Showcases Respiratory Innovation and Leadership
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that 20 abstracts related to Dupixent® (dupilumab) and the investigational therapy itepekimab will be presented at the European Respiratory Society (ERS) Congress 2024,…
Bristol Myers Squibb to Showcase Cardiovascular Portfolio Data at the European Society of Cardiology Congress 2024
Bristol Myers Squibb (NYSE: BMY) has announced that it will present research findings from its comprehensive cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, scheduled for August 30…
Invenra’s INV724 Gets FDA Rare Pediatric Disease and Orphan Drug Designations for Neuroblastoma
Invenra Inc. is excited to announce that its cutting-edge bispecific antibody, INV724, designed for neuroblastoma treatment, has received both Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) Designations from the…